



**Leadership Team**

**Michael Stocum, MS**  
President & Chief Executive Officer

**Matt Kostura, PhD**  
Chief Scientific Officer

**Alan Cooper, PhD**  
Head of Chemistry

**Andy Anantha, PhD**  
Head of CMC

**Todd Hembrough, PhD**  
Translational Medicine Advisor

**Mike Luther, PhD, MBA**  
Founding CEO, Board Advisor

**Scientific Advisory Board**

**David Weinstock, MD**  
Dana-Farber Cancer Institute

**Briggs Morrison, MD**  
CEO, Syndax, Inc.

**Mike Patane, PhD**  
President, Mitobridge/Astellas

**Mark Manfredi, PhD**  
CEO, Kyn Therapeutics

**Adrian Schwarzer, MD, PhD**  
Hanover Medical School

**Josh Rabinowitz, MD, PhD**  
Princeton University

**Rainer Fuchs, PhD**  
Former CIO Harvard Medical School; Biogen & GSK R&D

**Industry**

Pharmaceuticals, Oncology

**Financing To date**

Private Investor Syndicate ~\$25M

**Company Founding**

August 2015 Delaware LLC

**Contact Information**

**BANTAM PHARMACEUTICAL**  
646-598-4823  
www.bantampharma.com  
info@bantampharma.com

**Highlights**

- Bantam is an oncology-focused biotech company developing novel therapeutics for difficult to treat hematological and solid tumors
- Clinical candidate, BTM-3566 is an orally available small molecule selective modulator of mitochondrial dynamics, a novel mechanism of action (MoA) that drives apoptosis
- Durable and complete tumor regressions demonstrated in diffuse large B-cell lymphoma (DLBCL) xenograft and PDX *in vivo* models as single agent, once daily oral dosing
- Rituximab demonstrated additive benefit with BTM-3566 in combination studies
- Safety pharmacology including 14-day dose related finding studies including CMC package complete; FDA IND (Investigational New Drug) application filing in late 2021
- Clinical Proof of Concept (PoC) planned in B-cell lymphomas, specifically DLBCL
- Extensive IP estate with patent protection through 2039
- Opportunity to leverage MoA as a platform to discover additional leads and indications
- Strong leadership team with scientific expertise in oncology drug development
- **Company seeks \$30-35M for First in Human Phase 1a/1b studies to generate a clinical PoC in 2023, establish discovery platform and value inflection point for potential exit**

**THERAPEUTIC ASSET:** Bantam was founded in 2015 when the predecessor program was acquired for \$6M and we have since leveraged \$18M of seed investment over four years to discover and develop our clinical candidate BTM-3566. This orally available small molecule acts via a novel tumor-specific mitochondrial-driven metabolic pathway involving the ATF4 integrated stress response. This unique MoA is distinct from any known therapeutic. Bantam is initially targeting B-cell lymphomas with unmet clinical need, specifically refractory/recurrent DLBCL, then expanding its pipeline based on the MoA and established biomarkers to select and treat other hematological malignancies and solid tumors.

**MARKET OPPORTUNITY:** Successful development and commercialization of Bantam compounds could positively impact the lives of >150,000 patients/year in the US alone and address a large US and global market. Total potential annual market for lymphoma and selected solid tumor therapies is estimated to be >\$10 Billion/year.

**Bantam Pharmaceutical is now expanding its base of investors and partners to join it in advancing its initial drug program into clinical studies.**

**EXPERIENCED TEAM:** Bantam leadership has a proven track record in oncology biopharma drug discovery and development; our advisory board features prominent executive leaders from successful drug development companies spanning start-ups through global pharma.

**INTELLECTUAL PROPERTY:** Bantam owns an intellectual property estate covering the compounds, chemical space, and their broad clinical utility. Bantam recently filed patent applications featuring additional claims related to mechanism and routes of administration as well as chemical development. The IP portfolio provides exclusivity for Bantam’s products through at least 2039.

**NEAR TERM MILESTONES AND CLINICAL PLAN:** Bantam is rapidly progressing an IND application for **BTM-3566** and is seeking partners and funding to initiate human clinical trials, including the PoC clinical studies and the launch of our novel discovery platform.

Key Milestones for BTM-3566	
Clinical Candidate Selection	Completed
IND-enabling studies & GMP manufacturing	In Progress
File IND	Q4 2021
Initiate Phase 1 studies	Early 2022